腎積水治療市場 - 按類型、適應症、診斷、治療、年齡層和全球預測，2024 年 - 2032 年

在該領域研發進步的推動下，2024 年至 2032 年間，全球腎積水治療市場的複合年成長率將達到 8.2%。隨著醫學科學不斷發現新的見解和技術，腎積水的創新治療方式正在出現。例如，2022 年 9 月，內華達大學裡諾分校的研究人員發現了兩種促進尿液從腎臟流向輸尿管的重要離子通道。他們探索了從腎盂到輸尿管的肌肉收縮機制，增強了對尿液運動的理解。合著者 Nathan Grainger 博士強調了這項研究對人類健康的重要性，因為它旨在開發針對腎積水治療的特定離子通道的療法。

這些進展為患有這種疾病的患者提供了有希望的解決方案，從而增加了對有效療法的需求。此外，醫療保健專業人員和患者對早期診斷和治療重要性的認知不斷提高，進一步推動了市場的成長。隨著人們越來越重視以患者為中心的照護和改善結果，迫切需要新的治療方法來解決腎積水的根本原因。因此，該領域不斷增加的研究和開發工作有助於滿足對先進療法不斷成長的需求。

整個腎積水治療行業根據類型、適應症、診斷、治療、年齡層和地區進行分類。

從2024年到2032年，外源性部分將經歷嚴格的發展。當醫療保健專業人員診斷和處理此類外在原因時，同時需要有效的治療方法來解決由此產生的腎積水。這項需求推動了持續的研究和開發工作，以創新能夠減輕症狀和保護腎功能的治療干預措施。因此，腎積水治療市場的需求不斷增加，因為它迎合了導致這種情況的多種原因。

從2024 年到2032 年，雙側腎積水部分的腎積水治療市場佔有率將出現顯著的複合年成長率。治療解決方案的需求。由於雙側腎積水可導致腎損傷和腎衰竭等嚴重併發症，因此對能夠緩解症狀並改善患者預後的創新治療方案的需求不斷增加。因此，隨著醫療保健提供者和患者尋求量身定做的干涉措施來解決雙側腎積水的複雜性並減輕其對腎功能的不利影響，腎積水治療市場的需求正在增加。

2024年至2032年，亞太地區腎積水治療市場將呈現出值得稱讚的複合年成長率。上升。此外，改善醫療基礎設施和獲得醫療服務的機會使更多的人能夠尋求這種疾病的診斷和治療。該地區人口老化和生活方式的改變進一步推動了對有效腎積水治療的需求。因此，製造商和醫療保健提供者對專為滿足亞太地區患者特定需求而量身定做的創新療法的需求大幅上升。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 腎臟疾病盛行率上升
    • 尿路感染相關患者人數增加
    • 對微創手術的需求不斷成長
    • 擴大採用先進的成像技術進行診斷
  • 產業陷阱與挑戰
    • 認知不足，治療費用高
• 成長潛力分析
• 監管環境
• 報銷場景
• 技術景觀
• 波特的分析
• PESTEL分析
• 流行病學展望
• 未來市場趨勢

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按類型，2018 - 2032

• 主要趨勢
• 單側腎積水
• 雙側腎積水

第 6 章：市場估計與預測：按指標分類，2018 年 - 2032 年

• 主要趨勢
• 固有的
  • 急性單側阻塞性泌尿道病
  • 腎結石
  • 膀胱癌
  • 膀胱結石
  • 尿道狹窄
  • 骨盆腔器官脫垂
  • 其他內在跡象
• 外在
  • 腹膜後纖維化
  • 卵巢靜脈症候群
  • 其他外在跡象

第 7 章：市場估計與預測：按診斷，2018 - 2032

• 主要趨勢
• 實驗室測試
  • 尿液分析
  • 全血球計數
  • 電解質分析
  • 其他實驗室測試
• 影像學
  • 超音波
  • 靜脈腎盂造影
  • KUB X光
  • CT掃描
  • 其他成像類型

第 8 章：市場估計與預測：按處理方式，2018 - 2032

• 主要趨勢
• 震波碎石術
• 腹腔鏡檢查
• 膀胱導尿術
• 類固醇治療
• 其他治療

第 9 章：市場估計與預測：按年齡層別分類，2018 年 - 2032 年

• 主要趨勢
• 成人
• 兒科

第 10 章：市場估計與預測：按地區分類，2018 年 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 11 章：公司簡介

• AbbVie Inc.
• Amgen Inc.
• The Anthem Group
• F. Hoffmann-La Roche Ltd.
• Nephrogenex Inc.
• Novartis AG
• Pfizer Inc.
• Phraxis Inc.
• Renal Associates P.A.
• Sanofi

Global Hydronephrosis Treatment Market will witness 8.2% CAGR between 2024 and 2032, propelled by advancements in research and development within the field. As medical science continues to uncover new insights and technologies, innovative treatment modalities for hydronephrosis are emerging. For instance, in September 2022, researchers at the University of Nevada, Reno, identified two essential ion channels facilitating urine flow from kidneys to ureters. They explored muscle contraction mechanisms from the renal pelvis to the ureters, enhancing comprehension of urine movement. Nathan Grainger, Ph.D., co-author, highlighted the significance of this research for human health, as it aims at developing therapeutics targeting specific ion channels for hydronephrosis treatment.

These developments offer promising solutions for patients suffering from this condition, driving up demand for effective therapies. Moreover, increased awareness among healthcare professionals and patients regarding the importance of early diagnosis and treatment further fuels market growth. With a growing emphasis on patient-centric care and improved outcomes, there's a pressing need for novel treatments that address the underlying causes of hydronephrosis. Consequently, the rising research and development efforts in this field are instrumental in meeting the escalating demand for advanced therapies.

The overall Hydronephrosis Treatment Industry is classified based on the type, indication, diagnosis, treatment, age group, and region.

The extrinsic segment will undergo rigorous development from 2024 to 2032. These conditions, such as tumors, pregnancy, or enlarged organs, can compress the urinary tract, leading to hydronephrosis. As healthcare professionals diagnose and manage such extrinsic causes, there's a concurrent need for effective treatments addressing the resulting hydronephrosis. This demand fuels ongoing research and development efforts to innovate therapeutic interventions capable of alleviating symptoms and preserving renal function. Consequently, the market for hydronephrosis treatments experiences increased demand as it caters to the diverse etiologies contributing to this condition.

The hydronephrosis treatment market share from the bilateral hydronephrosis segment will register a notable CAGR from 2024 to 2032. This condition, characterized by the obstruction of both kidneys, presents unique challenges that drive the need for effective therapeutic solutions. As bilateral hydronephrosis can lead to severe complications such as kidney damage and renal failure, there is a heightened demand for innovative treatment options that can alleviate symptoms and improve patient outcomes. Consequently, the market for hydronephrosis treatments is experiencing increased demand as healthcare providers and patients seek interventions tailored to address the complexities of bilateral hydronephrosis and mitigate its adverse effects on renal function.

Asia Pacific hydronephrosis treatment market will showcase a commendable CAGR from 2024 to 2032. With a growing population and increasing awareness of urological conditions, there is a rising prevalence of hydronephrosis cases in the region. Additionally, improving healthcare infrastructure and access to medical services enable more individuals to seek diagnosis and treatment for this condition. The demand for effective hydronephrosis treatments is further fueled by the region's aging population and changing lifestyle patterns. As a result, manufacturers and healthcare providers are witnessing a significant uptick in demand for innovative therapies tailored to meet the specific needs of patients in the Asia-Pacific region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of kidney diseases
    • 3.2.1.2 Increasing patient population related to urinary tract infections
    • 3.2.1.3 Growing demand for minimally invasive procedures
    • 3.2.1.4 Increasing adoption of advanced imaging techniques for diagnosis
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of awareness and high treatment cost
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technological landscape
• 3.7 Porter's analysis
  • 3.7.1 Supplier power
  • 3.7.2 Buyer power
  • 3.7.3 Threat of new entrants
  • 3.7.4 Threat of substitutes
  • 3.7.5 Industry rivalry
• 3.8 PESTEL analysis
• 3.9 Epidemiology outlook
• 3.10 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Unilateral hydronephrosis
• 5.3 Bilateral hydronephrosis

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Intrinsic
  • 6.2.1 Acute unilateral obstructive uropathy
  • 6.2.2 Kidney stone
  • 6.2.3 Bladder cancer
  • 6.2.4 Bladder stones
  • 6.2.5 Urethral stricture
  • 6.2.6 Pelvic organ prolapse
  • 6.2.7 Other intrinsic indications
• 6.3 Extrinsic
  • 6.3.1 Retroperitoneal fibrosis
  • 6.3.2 Ovarian vein syndrome
  • 6.3.3 Other extrinsic indications

Chapter 7 Market Estimates and Forecast, By Diagnosis, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Laboratory tests
  • 7.2.1 Urinalysis
  • 7.2.2 Complete blood count
  • 7.2.3 Electrolyte analysis
  • 7.2.4 Other laboratory tests
• 7.3 Imaging
  • 7.3.1 Ultrasound
  • 7.3.2 Intravenous pyelography
  • 7.3.3 KUB X-Rays
  • 7.3.4 CT-scan
  • 7.3.5 Other imaging types

Chapter 8 Market Estimates and Forecast, By Treatment, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Shock wave lithotripsy
• 8.3 Laparoscopy
• 8.4 Bladder catheterization
• 8.5 Steroid therapy
• 8.6 Other treatments

Chapter 9 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Adult
• 9.3 Pediatric

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Amgen Inc.
• 11.3 The Anthem Group
• 11.4 F. Hoffmann-La Roche Ltd.
• 11.5 Nephrogenex Inc.
• 11.6 Novartis AG
• 11.7 Pfizer Inc.
• 11.8 Phraxis Inc.
• 11.9 Renal Associates P.A.
• 11.10 Sanofi